National Center for Health Statistics (NCHS), ICD-10 Coordination and Maintenance (C&M) Committee Meeting, 3549-3550 [2022-01283]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 15 / Monday, January 24, 2022 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–01262 Filed 1–21–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Center for Health Statistics
(NCHS), ICD–10 Coordination and
Maintenance (C&M) Committee
Meeting
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice of virtual meeting.
The CDC, National Center for
Health Statistics (NCHS), Classifications
and Public Health Data Standards Staff,
announces the following meeting of the
ICD–10 Coordination and Maintenance
(C&M) Committee meeting. This
meeting is open to the public, limited
only by audio lines available. Online
Registration is not required.
SUMMARY:
The meeting will be held on
March 8, 2022, from 9:00 a.m. to 5:00
p.m., EST, and March 9, 2022, from 9:00
a.m. to 5:00 p.m., EST.
DATES:
This is a virtual meeting.
Information will be provided on each of
our respective web pages when it
becomes available. For CDC/NCHS
https://www.cdc.gov/nchs/icd/icd10cm_
maintenance.htm. For CMS https://
www.cms.gov/Medicare/Coding/
ICD9ProviderDiagnosticCodes/meetings.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Traci Ramirez, Medical Systems
Specialist, CDC, 3311 Toledo Road,
Hyattsville, Maryland 20782,
Telephone: (301) 458–4454; Email:
TRamirez@cdc.gov.
jspears on DSK121TN23PROD with NOTICES1
SUPPLEMENTARY INFORMATION:
Purpose: The ICD–10 Coordination
and Maintenance (C&M) Committee is a
public forum for the presentation of
proposed modifications to the
International Classification of Diseases,
Tenth Revision, Clinical Modification
and ICD–10 Procedure Coding System.
Matters To Be Considered: The
tentative agenda will include
discussions on ICD–10–CM and ICD–
10–PCS topics listed below. Agenda
items are subject to change as priorities
dictate. Please refer to the posted agenda
for updates one month prior to the
meeting.
VerDate Sep<11>2014
18:11 Jan 21, 2022
Jkt 256001
ICD–10–PCS Topics
1. Administration of Spesolimab *
2. Administration of daratumumab and
hyaluronidase-fihj *
3. Administration of Defencath *
4. Administration of Maribavir *
5. Administration of Teclistamab *
6. Administration of Mosunetuzumab *
7. Administration of afamitresgene
autoleucel **
8. Administration of tabelecleucel **
9. Administration of Treosulfan *
10. Administration of inebilizumab-cdon *
11. Administration of Xenon-129 *
12. Administration of betibeglogene
autotemcel **
13. Administration of Omidubicel **
14. Implantation of Sphenopalatine Ganglion
Stimulator for Ischemic Stroke *
15. Gene Expression Assay **
16. Vertebral Body Tethering *
17. Percutaneous Femoral-Popliteal Artery
Bypass *
18. Computer-Assisted Transcranial Magnetic
Stimulation *
19. Computer-Aided Analysis for the
Detection and Classification of Epileptic
Events *
20. Facet Replacement Spinal Stabilization
Device *
21. Insertion of Sacropelvic Fixation
System *
22. Insertion of an Implantable Vagus Nerve
Stimulation System *
23. Insertion of a Paired Vagus Nerve
Stimulation System *
24. Percutaneous Venous Thrombectomy for
Postthrombotic Syndrome *
25. Quantitative Flow Ratio for Non-invasive
Intraprocedural Analysis of Cardiac
Angiography
26. Application of Allogeneic Thymus
Derived Tissue
27. Supersaturated Oxygen Therapy
28. Assistance with Precision Stimulation
Software *
29. Section X Updates
30. Addenda and Key Updates
* Requestor has submitted a New
Technology Add-on Payment (NTAP)
application for FY 2023.
** Requestor intends to submit an
NTAP application for FY 2024
consideration.
Presentations for procedure code
requests are conducted by both the
requestor and CMS during the
Coordination & Maintenance Committee
meeting. Discussion from the requestor
generally focuses on the clinical issues
for the procedure or technology,
followed by the proposed coding
options from a CMS analyst. Topics
presented may also include requests for
new procedure codes that relate to a
new technology add-on payment
(NTAP) policy request.
CMS is continuing to modify the
approach for presenting the new
technology add-on payment (NTAP)
related ICD–10–PCS procedure code
requests that involve the administration
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
3549
of a therapeutic agent for the March 8–
9, 2022 ICD–10 Coordination and
Maintenance Committee meeting.
Consistent with the requirements of
section 1886(d)(5)(K)(iii) of the Social
Security Act, applicants submitted
requests to create a unique procedure
code to describe the administration of a
therapeutic agent, such as the option to
create a new code in Section X within
the ICD–10–PCS procedure code
classification. CMS will initially only
display those meeting materials
associated with the NTAP related ICD–
10–PCS procedure code requests that
involve the administration of a
therapeutic agent on the CMS website in
early February 2022 at: https://
www.cms.gov/Medicare/Coding/ICD10/
C-and-M-Meeting-Materials.
The 13 NTAP related ICD–10–PCS
procedure code requests that involve the
administration of a therapeutic agent
are:
1. Administration of Spesolimab *
2. Administration of daratumumab and
hyaluronidase-fihj *
3. Administration of Defencath *
4. Administration of Maribavir *
5. Administration of Teclistamab *
6. Administration of Mosunetuzumab *
7. Administration of afamitresgene
autoleucel **
8. Administration of tabelecleucel **
9. Administration of Treosulfan *
10. Administration of inebilizumab-cdon *
11. Administration of Xenon-129 *
12. Administration of betibeglogene
autotemcel **
13. Administration of Omidubicel **
These topics will not be presented
during the March 8–9, 2022 meeting.
CMS will solicit public comments
regarding any clinical questions or
coding options included for these 13
procedure code topics in advance of the
meeting continuing through the end of
the public comment period, April 8,
2022. Members of the public should
send any questions or comments to the
CMS mailbox at: ICDProcedure
CodeRequest@cms.hhs.gov by the April
8, 2022 deadline.
CMS intends to post a question and
answer document in advance of the
meeting to address any clinical or
coding questions that members of the
public may have submitted. Following
the conclusion of the meeting, CMS will
post an updated question and answer
document to address any additional
clinical or coding questions that
members of the public may have
submitted during the meeting that CMS
was not able to address or that were
submitted after the meeting.
The NTAP related ICD–10–PCS
procedure code requests that do not
involve the administration of a
E:\FR\FM\24JAN1.SGM
24JAN1
3550
Federal Register / Vol. 87, No. 15 / Monday, January 24, 2022 / Notices
therapeutic agent and all non-NTAP
related procedure code requests will
continue to be presented during the
virtual meeting on March 8, 2022,
consistent with the standard meeting
process.
CMS will make all meeting materials
and related documents available at:
https://www.cms.gov/Medicare/Coding/
ICD10/C-and-M-Meeting-Materials. Any
inquiries related to the procedure code
topics scheduled for the March 8–9,
2022 ICD–10 Coordination and
Maintenance Committee meeting that
are under consideration for October 1,
2022 implementation should be sent to
the CMS mailbox at: ICDProcedure
CodeRequest@cms.hhs.gov.
ICD–10–CM Topics
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–01283 Filed 1–21–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; ORR–1, Cash and Medical
Assistance Program Estimates
Office of Refugee Resettlement,
Administration for Children and
Families, HHS.
ACTION: Request for public comment.
AGENCY:
1. Coma
2. Craniosynostosis
3. Extraocular muscle entrapment
4. Foreign body sensation
5. Impairing Emotional Outbursts
6. Insulin resistant syndrome
7. Leukodystrophies
8. Observation and evaluation of newborn for
other specified suspected condition ruled
out
9. Problems related to upbringing
10. Addenda
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
The Office of Refugee
Resettlement (ORR), Administration for
Children and Families (ACF), U.S.
Department of Health and Human
Services (HHS) is requesting a 3-year
extension of the form ORR–1, Cash and
Medical Assistance Program Estimates
(OMB #0970–0030, expiration 5/31/
2022). There are no changes requested
to the form or instructions.
DATES: Comments due within 60 days of
publication. In compliance with the
requirements of section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
ACF is soliciting public comment on the
specific aspects of the information
collection described above.
SUMMARY:
Copies of the proposed
collection of information can be
obtained and comments may be
forwarded by emailing infocollection@
acf.hhs.gov. Identify all requests by the
title of the information collection.
SUPPLEMENTARY INFORMATION:
Description: The ORR–1, Cash and
Medical Assistance Program Estimates,
is the application for grants under the
Cash and Medical Assistance (CMA)
program. The application is required by
ORR program regulations at 45 CFR
400.11(b). The regulation specifies that
states must submit, as their application
for this program, estimates of the
projected costs they anticipate incurring
in providing cash and medical
assistance for eligible recipients and the
costs of administering the program.
Under the CMA program, states are
reimbursed for the costs of providing
these services and benefits for 8 months
after an eligible recipient arrives in this
country. The eligible recipients for these
services and benefits are refugees,
Amerasians, Cuban and Haitian
Entrants, asylees, Afghans and Iraqi
with Special Immigrant Visas, and
victims of a severe form of trafficking.
States that provide services for
unaccompanied refugee minors also
provide an estimate for the cost of these
services for the year for which they are
applying for grants.
Respondents: State Agencies, the
District of Columbia, and Replacement
Designees under 45 CFR 400.301(c)
administering or supervising the
administration of programs under Title
IV of the Act.
ADDRESSES:
jspears on DSK121TN23PROD with NOTICES1
ANNUAL BURDEN ESTIMATES
Instrument
Total
number of
respondents
Annual
number of
responses per
respondent
Average
burden hours
per response
Annual
burden hours
ORR–1, Cash and Medical Assistance Program Estimates ...........................
57
1
0.6
34
Estimated Total Annual Burden
Hours: 34.
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
VerDate Sep<11>2014
18:11 Jan 21, 2022
Jkt 256001
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
(Authority: 8 U.S.C. 412(a)(4))
[FR Doc. 2022–01287 Filed 1–21–22; 8:45 am]
PO 00000
Administration for Children and
Families
Privacy Act of 1974; System of
Records
Mary B. Jones,
ACF/OPRE Certifying Officer.
BILLING CODE 4184–45–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children
and Families, Department of Health and
Human Services.
AGENCY:
ACTION:
Notice of modified systems of
records.
In accordance with the
requirements of the Privacy Act of 1974,
SUMMARY:
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\24JAN1.SGM
24JAN1
]]>Agencies
[Federal Register Volume 87, Number 15 (Monday, January 24, 2022)]
[Notices]
[Pages 3549-3550]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01283]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for Health Statistics (NCHS), ICD-10 Coordination
and Maintenance (C&M) Committee Meeting
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of virtual meeting.
-----------------------------------------------------------------------
SUMMARY: The CDC, National Center for Health Statistics (NCHS),
Classifications and Public Health Data Standards Staff, announces the
following meeting of the ICD-10 Coordination and Maintenance (C&M)
Committee meeting. This meeting is open to the public, limited only by
audio lines available. Online Registration is not required.
DATES: The meeting will be held on March 8, 2022, from 9:00 a.m. to
5:00 p.m., EST, and March 9, 2022, from 9:00 a.m. to 5:00 p.m., EST.
ADDRESSES: This is a virtual meeting. Information will be provided on
each of our respective web pages when it becomes available. For CDC/
NCHS https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm. For CMS
https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.
FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Medical Systems
Specialist, CDC, 3311 Toledo Road, Hyattsville, Maryland 20782,
Telephone: (301) 458-4454; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is
a public forum for the presentation of proposed modifications to the
International Classification of Diseases, Tenth Revision, Clinical
Modification and ICD-10 Procedure Coding System.
Matters To Be Considered: The tentative agenda will include
discussions on ICD-10-CM and ICD-10-PCS topics listed below. Agenda
items are subject to change as priorities dictate. Please refer to the
posted agenda for updates one month prior to the meeting.
ICD-10-PCS Topics
1. Administration of Spesolimab *
2. Administration of daratumumab and hyaluronidase-fihj *
3. Administration of Defencath *
4. Administration of Maribavir *
5. Administration of Teclistamab *
6. Administration of Mosunetuzumab *
7. Administration of afamitresgene autoleucel **
8. Administration of tabelecleucel **
9. Administration of Treosulfan *
10. Administration of inebilizumab-cdon *
11. Administration of Xenon-129 *
12. Administration of betibeglogene autotemcel **
13. Administration of Omidubicel **
14. Implantation of Sphenopalatine Ganglion Stimulator for Ischemic
Stroke *
15. Gene Expression Assay **
16. Vertebral Body Tethering *
17. Percutaneous Femoral-Popliteal Artery Bypass *
18. Computer-Assisted Transcranial Magnetic Stimulation *
19. Computer-Aided Analysis for the Detection and Classification of
Epileptic Events *
20. Facet Replacement Spinal Stabilization Device *
21. Insertion of Sacropelvic Fixation System *
22. Insertion of an Implantable Vagus Nerve Stimulation System *
23. Insertion of a Paired Vagus Nerve Stimulation System *
24. Percutaneous Venous Thrombectomy for Postthrombotic Syndrome *
25. Quantitative Flow Ratio for Non-invasive Intraprocedural
Analysis of Cardiac Angiography
26. Application of Allogeneic Thymus Derived Tissue
27. Supersaturated Oxygen Therapy
28. Assistance with Precision Stimulation Software *
29. Section X Updates
30. Addenda and Key Updates
* Requestor has submitted a New Technology Add-on Payment (NTAP)
application for FY 2023.
** Requestor intends to submit an NTAP application for FY 2024
consideration.
Presentations for procedure code requests are conducted by both the
requestor and CMS during the Coordination & Maintenance Committee
meeting. Discussion from the requestor generally focuses on the
clinical issues for the procedure or technology, followed by the
proposed coding options from a CMS analyst. Topics presented may also
include requests for new procedure codes that relate to a new
technology add-on payment (NTAP) policy request.
CMS is continuing to modify the approach for presenting the new
technology add-on payment (NTAP) related ICD-10-PCS procedure code
requests that involve the administration of a therapeutic agent for the
March 8-9, 2022 ICD-10 Coordination and Maintenance Committee meeting.
Consistent with the requirements of section 1886(d)(5)(K)(iii) of the
Social Security Act, applicants submitted requests to create a unique
procedure code to describe the administration of a therapeutic agent,
such as the option to create a new code in Section X within the ICD-10-
PCS procedure code classification. CMS will initially only display
those meeting materials associated with the NTAP related ICD-10-PCS
procedure code requests that involve the administration of a
therapeutic agent on the CMS website in early February 2022 at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials.
The 13 NTAP related ICD-10-PCS procedure code requests that involve
the administration of a therapeutic agent are:
1. Administration of Spesolimab *
2. Administration of daratumumab and hyaluronidase-fihj *
3. Administration of Defencath *
4. Administration of Maribavir *
5. Administration of Teclistamab *
6. Administration of Mosunetuzumab *
7. Administration of afamitresgene autoleucel **
8. Administration of tabelecleucel **
9. Administration of Treosulfan *
10. Administration of inebilizumab-cdon *
11. Administration of Xenon-129 *
12. Administration of betibeglogene autotemcel **
13. Administration of Omidubicel **
These topics will not be presented during the March 8-9, 2022
meeting. CMS will solicit public comments regarding any clinical
questions or coding options included for these 13 procedure code topics
in advance of the meeting continuing through the end of the public
comment period, April 8, 2022. Members of the public should send any
questions or comments to the CMS mailbox at: ICDProcedure
[email protected] by the April 8, 2022 deadline.
CMS intends to post a question and answer document in advance of
the meeting to address any clinical or coding questions that members of
the public may have submitted. Following the conclusion of the meeting,
CMS will post an updated question and answer document to address any
additional clinical or coding questions that members of the public may
have submitted during the meeting that CMS was not able to address or
that were submitted after the meeting.
The NTAP related ICD-10-PCS procedure code requests that do not
involve the administration of a
[[Page 3550]]
therapeutic agent and all non-NTAP related procedure code requests will
continue to be presented during the virtual meeting on March 8, 2022,
consistent with the standard meeting process.
CMS will make all meeting materials and related documents available
at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials. Any inquiries related to the procedure code topics scheduled
for the March 8-9, 2022 ICD-10 Coordination and Maintenance Committee
meeting that are under consideration for October 1, 2022 implementation
should be sent to the CMS mailbox at: ICDProcedure
[email protected].
ICD-10-CM Topics
1. Coma
2. Craniosynostosis
3. Extraocular muscle entrapment
4. Foreign body sensation
5. Impairing Emotional Outbursts
6. Insulin resistant syndrome
7. Leukodystrophies
8. Observation and evaluation of newborn for other specified
suspected condition ruled out
9. Problems related to upbringing
10. Addenda
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-01283 Filed 1-21-22; 8:45 am]
BILLING CODE 4163-18-P
